Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114486

Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

P Hildebrand, C Beglinger, K Gyr, J B Jansen, L C Rovati, M Zuercher, C B Lamers, I Setnikar, and G A Stalder

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Hildebrand, P. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Beglinger, C. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Gyr, K. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Jansen, J. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Rovati, L. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Zuercher, M. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Lamers, C. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Setnikar, I. in: PubMed | Google Scholar

Division of Gastroenterology, University Hospital, Basel, Switzerland.

Find articles by Stalder, G. in: PubMed | Google Scholar

Published March 1, 1990 - More info

Published in Volume 85, Issue 3 on March 1, 1990
J Clin Invest. 1990;85(3):640–646. https://doi.org/10.1172/JCI114486.
© 1990 The American Society for Clinical Investigation
Published March 1, 1990 - Version history
View PDF
Abstract

The present study was designed (a) to characterize the activity of loxiglumide as a peripheral cholecystokinin (CCK) antagonist in healthy human subjects, and (b) to determine whether CCK is a physiologic regulator of the intestinal phase of meal-stimulated exocrine pancreatic and biliary secretions in man. Intravenous loxiglumide (22 mumol/kg per h) was highly potent in antagonizing CCK8-induced pancreatic enzyme and bile acid secretion as well as pancreatic polypeptide release. The potency and selectivity of loxiglumide as an antagonist of CCK provides the tool for evaluating the role of CCK as a physiological mediator of meal-induced pancreatic and biliary responses in humans. Infusion of a liquid test meal into the duodenum evoked an immediate response of pancreatic enzyme and bilirubin outputs, respectively. Intravenous loxiglumide significantly inhibited the meal-induced pancreatic amylase output by 63% (P less than 0.05), lipase output by 43% (P less than 0.05), and bilirubin output by 59% (P less than 0.05). These data suggest that CCK is a physiological mediator of the intestinal phase of meal-stimulated pancreatic and biliary responses.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 640
page 640
icon of scanned page 641
page 641
icon of scanned page 642
page 642
icon of scanned page 643
page 643
icon of scanned page 644
page 644
icon of scanned page 645
page 645
icon of scanned page 646
page 646
Version history
  • Version 1 (March 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts